Contineum Therapeutics, Inc.
CTNM
$12.15
-$0.07-0.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.95% | 62.55% | 81.99% | 97.89% | 85.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.72% | 56.21% | 70.99% | 52.50% | 50.03% |
| Operating Income | -33.72% | -56.21% | -70.99% | -624.55% | -416.57% |
| Income Before Tax | -41.93% | -66.71% | -79.23% | -354.54% | -282.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -41.93% | -67.47% | -80.82% | -360.53% | -285.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.93% | -67.47% | -80.82% | -360.53% | -285.99% |
| EBIT | -33.72% | -56.21% | -70.99% | -624.55% | -416.57% |
| EBITDA | -33.77% | -56.29% | -71.12% | -613.76% | -411.19% |
| EPS Basic | 55.47% | 53.45% | 69.17% | 0.65% | -445.15% |
| Normalized Basic EPS | 55.46% | 70.79% | 78.14% | -122.43% | -148.03% |
| EPS Diluted | 55.47% | 53.45% | 69.17% | 60.33% | -214.58% |
| Normalized Diluted EPS | 55.46% | 70.79% | 78.14% | -611.05% | -523.21% |
| Average Basic Shares Outstanding | 43.36% | 96.48% | 239.94% | 980.37% | 736.63% |
| Average Diluted Shares Outstanding | 43.36% | 96.48% | 239.94% | 773.76% | 575.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |